Neurological Disorders

Minocycline in ALS Sponsor Columbia University and N.I.H. Berman Center Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description The purpose of this study is to investigate if minocycline slows ALS progression. All study visits and evaluations are performed at the Berman Center.
Co-Enzyme-Q-10 in ALS Sponsor Columbia University and N.I.H. Berman Center Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description The purpose of this study is to evaulate if high dose Co-Enzyme-Q-10 slows functional decline in ALS. All study visits and evaluations are performed at the Berman Center.
IGF-I (Myotrophin) in ALS Sponsor Great Lakes ALS Consortium Principal Investigator Eric Sorenson, MD, Mayo Clinic, Rochester, Minnesota Berman Center Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description This project, tests the efficacy of the investigational drug IGF-I (Insulin-like Growth Factor) for slowing the progression of ALS. IGF-I is a growth factor that has shown promise in protecting the motor neurons in the brain and spinal cord. The study is a double-blinded, placebo-controlled trial in which intervention lasts for 24 months. This study is closed to enrollment.
TCH-346 Sponsor Novartis Pharmaceuticals Berman Center Site Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description TCH 346 is an investigational oral medication, that may slow the progression of ALS (almyotrophic lateral sclerosis) by interfering with a glycolytic enzyme that is suspected of causing programmed death of motor neuron cells. This study has been completed.
VEST-A device study for ALS patients Sponsor Advanced Respiratory Berman Center Site Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description The VEST is a device that the patient wears which oscillates the patient’s chest wall at high frequencies to keep the airway clear. The purpose of this study is to test the hypothesis that use of the VEST for three months will prevent pulmonary complications, such as pneumonia, in ALS patients. This study has been completed.
Celebrex in ALS (Amyotrophic Lateral Sclerosis) Principal Investigator Merit Cudkowicz, MD Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts Berman Center Site Investigator William David, MD, PhD Berman Center Site Coordinator Shirley Conn, RN, 612-341-7907 Description This study enrolled 300 ALS patients across the U.S., whose disease duration had been less than two years. It was a placebo-controlled, double-blinded study to evaluate the efficacy of Celebrex in slowing the progression of ALS during the 12-month intervention period. This study has been completed.